Id: | acc1428 |
Group: | 2sens |
Protein: | IRS1 |
Gene Symbol: | IRS1 |
Protein Id: | P35568 |
Protein Name: | IRS1_HUMAN |
PTM: | phosphorylation |
Site: | Ser1101 |
Site Sequence: | PQGCRRRHSSETFSSTPSATR |
Disease Category: | Cancer |
Disease: | Lung Cancer |
Disease Subtype: | NSCLC |
Disease Cellline: | A549 |
Disease Info: | |
Drug: | ZNF323A OV |
Drug Info: | - |
Effect: | modulate |
Effect Info: | The drug causes protein phosphorylation and promotes tumor autophagy. |
Note: | Non-conventional drugs |
Score: | 3.0 |
Pubmed(PMID): | 32576196 |
Sentence Index: | 32576196_6-7 |
Sentence: | "Thus, we further investigated the molecular regulation of ZNF322A, and found the inhibitory transcriptional regulation of ZNF322A on PIM3, which was able to phosphorylate IRS1 at serine1101 in order to manipulate glucose uptake via the PI3K/AKT/mTOR signaling pathway. Moreover, ZNF322A also affects the unfolded protein response by phosphorylation of HSP27S82 and eIF2aS51, and triggers autophagosome formation in lung cancer cells." |
Sequence & Structure:
MASPPESDGFSDVRKVGYLRKPKSMHKRFFVLRAASEAGGPARLEYYENEKKWRHKSSAPKRSIPLESCFNINKRADSKNKHLVALYTRDEHFAIAADSEAEQDSWYQALLQLHNRAKGHHDGAAALGAGGGGGSCSGSSGLGEAGEDLSYGDVPPGPAFKEVWQVILKPKGLGQTKNLIGIYRLCLTSKTISFVKLNSEAAAVVLQLMNIRRCGHSENFFFIEVGRSAVTGPGEFWMQVDDSVVAQNMHETILEAMRAMSDEFRPRSKSQSSSNCSNPISVPLRRHHLNNPPPSQVGLTRRSRTESITATSPASMVGGKPGSFRVRASSDGEGTMSRPASVDGSPVSPSTNRTHAHRHRGSARLHPPLNHSRSIPMPASRCSPSATSPVSLSSSSTSGHGSTSDCLFPRRSSASVSGSPSDGGFISSDEYGSSPCDFRSSFRSVTPDSLGHTPPARGEEELSNYICMGGKGPSTLTAPNGHYILSRGGNGHRCTPGTGLGTSPALAGDEAASAADLDNRFRKRTHSAGTSPTITHQKTPSQSSVASIEEYTEMMPAYPPGGGSGGRLPGHRHSAFVPTRSYPEEGLEMHPLERRGGHHRPDSSTLHTDDGYMPMSPGVAPVPSGRKGSGDYMPMSPKSVSAPQQIINPIRRHPQRVDPNGYMMMSPSGGCSPDIGGGPSSSSSSSNAVPSGTSYGKLWTNGVGGHHSHVLPHPKPPVESSGGKLLPCTGDYMNMSPVGDSNTSSPSDCYYGPEDPQHKPVLSYYSLPRSFKHTQRPGEPEEGARHQHLRLSTSSGRLLYAATADDSSSSTSSDSLGGGYCGARLEPSLPHPHHQVLQPHLPRKVDTAAQTNSRLARPTRLSLGDPKASTLPRAREQQQQQQPLLHPPEPKSPGEYVNIEFGSDQSGYLSGPVAFHSSPSVRCPSQLQPAPREEETGTEEYMKMDLGPGRRAAWQESTGVEMGRLGPAPPGAASICRPTRAVPSSRGDYMTMQMSCPRQSYVDTSPAAPVSYADMRTGIAAEEVSLPRATMAAASSSSAASASPTGPQGAAELAAHSSLLGGPQGPGGMSAFTRVNLSPNRNQSAKVIRADPQGCRRRHSSETFSSTPSATRVGNTVPFGAGAAVGGGGGSSSSSEDVKRHSSASFENVWLRPGELGGAPKEPAKLCGAAGGLENGLNYIDLDLVKDFKQCPQECTPEPQPPPPPPPHQPLGSGESSSTRRSSEDLSAYASISFQKQPEDRQ
Select PDB:
No data.
Protein Tractability:
source: Open TargetsPTM Intensity:
source: CPTACIRS1-Ser1101 | |
---|---|
Cancer | Intensity |
BRCA | -1.279 |
COAD | 0.625 |
HGSC | 1.291 |
ccRCC | |
GBM | |
HNSC | 0.786 |
LUAD | 0.106 |
LUSC | 0.608 |
non_ccRCC | |
PDAC | -1.182 |
UCEC | -0.955 |
PTM-Disease Association:
source: PTMDResidue | Position | State | Disease | Class | PMID |
---|---|---|---|---|---|
S | 1101 | U | Diabetes mellitus | Phosphorylation | 17709744 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMProtein | Gene | PTM | Position | Modified sequence | Cell | Drug | pEC50 | Regulation | Experiment |
---|---|---|---|---|---|---|---|---|---|
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | HeLa | Curcumin | 4.3872 | down | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | K562 | Paclitaxel | 6.7803 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A549 | Refametinib | 9.9339 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A549 | Staursporin | 8.5271 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A549 | Tideglusib | 7.0267 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | BT-474 | Lapatinib | 6.7559 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | BT-474 | Trastuzumab | -1.3664 | - | |
P35568 | IRS1 | P | Ser1101 | RHSS(ph)ETFSSTPSATR | HeLa | A485 | 11.1331 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | HeLa | A485 | 6.3985 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | HeLa | CUDC101 | 5.7343 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | HeLa | Romidepsin | 12.6447 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | HeLa | SAHA | 6.5242 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | K562 | Cytarabine | 8.2629 | - | |
P35568 | IRS1 | P | Ser1101 | RHSS(ph)ETFSSTPSATR | A549 | Pictilisib | 8.7629 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | MDA-MB-175 | Lapatinib | 6.6835 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | MDA-MB-175 | Pertuzumab | -3.2528 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | MDA-MB-175 | Trastuzumab | -4.7413 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | PC-9 | AZD4547 | 5.2544 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | PC-9 | Gefitinib | 1.5229 | - | |
P35568 | IRS1 | P | Ser1101 | RHSS(ph)ETFSSTPSATR | PC-9 | GeftinibAZD4547-1to80 | 8.0131 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | PC-9 | GeftinibAZD4547-1to80 | 7.7653 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | PC-9 | Lapatinib | 5.2545 | - | |
P35568 | IRS1 | P | Ser1101 | RHSS(ph)ETFSSTPSATR | PC-9 | LapatinibAZD4547 | 5.2605 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | PC-9 | LapatinibAZD4547 | 5.1432 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | Ramos | Rituximab | 2.0339 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | Ramos | Rituximab | -2.2156 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A459 | SelumetinibMK2206-3to1 | 4.9357 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A431 | Afatinib | 7.7621 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A431 | Dasatinib | 6.5822 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A431 | Dasatinib | 12.7548 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A431 | Imatinib | 12.5659 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A459 | MK2206 | 6.2632 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A459 | MK2206 | 5.7767 | - | |
P35568 | IRS1 | P | Ser1101 | RHSS(ph)ETFSSTPSATR | A459 | MK2206 | 4.7556 | - | |
P35568 | IRS1 | P | Ser1101 | RHSS(ph)ETFSSTPSATR | A459 | Selumetinib | 8.2421 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A459 | Selumetinib | 8.0195 | - | |
P35568 | IRS1 | P | Ser1101 | RHSS(ph)ETFSSTPSATR | A459 | Selumetinib | 7.0015 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A459 | Selumetinib | 1.5229 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A459 | SelumetinibMK2206-1to2 | 6.3989 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A431 | Afatinib | 9.2553 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A549 | AZD8055 | 7.7619 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A549 | Dactolisib | 15 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A549 | Dasatinib | 7.2286 | - | |
P35568 | IRS1 | P | Ser1101 | RHSS(ph)ETFSSTPSATR | A549 | Dasatinib | 7.0182 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A549 | Dasatinib | 6.2616 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A549 | MK2206 | 6.2973 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A549 | Nintedanib | 10.9095 | - | |
P35568 | IRS1 | P | Ser1101 | RHSS(ph)ETFSSTPSATR | A549 | Nintedanib | 6.7567 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A549 | PD325901 | 9.0184 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A549 | PD325901 | 5.7949 | - | |
P35568 | IRS1 | P | Ser1101 | RHSS(ph)ETFSSTPSATR | A549 | PD325901 | 5.0924 | - | |
P35568 | IRS1 | P | Ser1101 | HSS(ph)ETFSSTPSATR | A549 | Pictilisib | 10.9818 | - |
pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.
Function score:
source: funscoRNo data.